Serazapine (developmental code name CGS-15040A) is a serotonin 5-HT2 receptor antagonist that was investigated as a potential treatment for generalized anxiety disorder in the 1990s. In humans, serazapine was well tolerated at doses of 10 to 40 mg and was found to be superior to placebo for reducing anxiety symptoms as indicated by HAM-A scores. However, clinical development was discontinued.
Attributes | Values |
---|---|
rdf:type | |
rdfs:label |
|
rdfs:comment |
|
foaf:depiction | |
dcterms:subject | |
Wikipage page ID |
|
Wikipage revision ID |
|
Link from a Wikipage to another Wikipage | |
sameAs | |
dbp:wikiPageUsesTemplate | |
thumbnail | |
ATC prefix |
|
c |
|
CAS number |
|
ChEMBL |
|
ChemSpiderID |
|
H |
|
IUPAC name |
|
n |
|
O |
|
PubChem |
|
routes of administration | |
SMILES |
|
StdInChI |
|
StdInChIKey |
|
synonyms |
|
UNII |
|
width |
|
has abstract |
|
prov:wasDerivedFrom | |
page length (characters) of wiki page |
|
CAS number |
|
ChEMBL |
|
FDA UNII code |
|
PubChem |
|
foaf:isPrimaryTopicOf | |
is Link from a Wikipage to another Wikipage of | |
is foaf:primaryTopic of |